Allergy Therapeutics Share Price (AGY)

0.00 0.00 (0.00%) delayed: 1:30AM GMT
Bid price 13.50 Open price 0.00
Ask price 14.50 Prev close 14.00
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live Allergy Therapeutics share prices, Allergy Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Allergy Therapeutics Level 2 Data, indepth research tools and investor commentary for Allergy Therapeutics (AGY) and other London Stock Exchange equities.

Allergy Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Allergy Therapeutics share price charts

Allergy Therapeutics Share Price Information

Name Allergy Therapeutics Epic AGY
Sector Pharmaceuticals & Biotechnology ISIN GB00B02LCQ05
Activites Allergy Therapeutics plc is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK. Index n/a

Allergy Therapeutics Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) 24.40
Market Capitalisation (£m) 89.06 Gross Gearing (%) 54.85
Shares in issue (m) 636.17 Debt Ratio 36.69
P/E Ratio -11.02 Debt-to-Equity Ratio 0.48
Total dividends per share (p) 0.00 Assets / Equity Ratio 2.22
Dividend Yield (%) 0.00 Price to book value 3.87
Dividend cover (x) 0.00 ROCE (%) -18.96
Earning per share (p) -1.27 EPS Growth (%) -202.38
52 week high / low 31.75 / 13.75 DPS Growth (%) n/a

Allergy Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
24/10/2018 BUY Manuel Llobet CEO 50,000
24/10/2018 BUY Nick Wykeman FD 150,000
24/10/2018 BUY Peter Jensen CH 20,000
12/10/2017 BUY Dr Tunde Otulana NED 25,000
29/09/2016 BUY Peter Jensen CH 30,000

More Allergy Therapeutics Director Deals >>

Allergy Therapeutics Company News

17:59 29/11/2018

Holdings in Company

RNS Number : 9774I Allergy Therapeutics PLC 29 November 2018   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i...

13:12 27/11/2018

Result of AGM

RNS Number : 6549I Allergy Therapeutics PLC 27 November 2018         Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")   Result of Annual General Meeting     27 November 2018 Allergy Therapeutics plc (AIM:AGY), the fully...

07:00 27/11/2018

AGM Trading Update

RNS Number : 5502I Allergy Therapeutics PLC 27 November 2018         Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group")    AGM Trading Update   Sales continue to grow strongly with market share gains     27 November 2018...

More Allergy Therapeutics Company News >>

Register now for FREE Allergy Therapeutics company news

Allergy Therapeutics Share Price Discussions

14 days ago

Allergy Therapeutics PLC (AGY)

Mission Statement To create a sustainable, fast-growing and profitable global speciality pharmaceutical business with a substantial franchise in the allergy sector by developing innovative, patented, registered therapies for both the treatment and prevention of allergy-related conditions....

more than 1 year ago

Allergy TV Clip re: Successful Phase II Study (AGY)

more than 1 year ago

Allergy Therapeutics (AGY)

Good morning, Below is a short TV interview with Manuel & Ian covering today's interim results.

Register now for FREE Allergy Therapeutics share price discussions